Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients

被引:47
作者
Feng, Wei-neng [1 ]
Gu, Wei-quan [2 ]
Zhao, Ning [2 ]
Pan, Ying-ming [3 ]
Luo, Wei [3 ]
Zhang, Hua [1 ]
Liang, Jian-miao [1 ]
Yang, Jie [2 ]
Deng, Yan-ming [1 ]
机构
[1] First Peoples Hosp Foshan, Dept Head & Neck Thorac Med Oncol, Foshan, Guangdong, Peoples R China
[2] First Peoples Hosp Foshan, Dept Thorac Surg, Foshan, Peoples R China
[3] First Peoples Hosp Foshan, Clin Res Inst, Foshan, Peoples R China
关键词
CIRCULATING TUMOR DNA; CELL-FREE DNA; PLASMA; GEFITINIB; ERLOTINIB; SURVIVAL; SAMPLES; TISSUE;
D O I
10.1016/j.tranon.2018.02.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Liquid biopsy is emerging as an important approach for tumor genotyping in non-small cell lung cancer, ddPCR and SuperARMS are both methods with high sensitivity and specificity for detecting EGFR mutation in plasma. We aimed to compare ddPCR and SuperARMS to detect plasma EGFR status in a cohort of advanced NSCLC patients. METHOD: A total of 79 tumor tissues and paired plasma samples were collected. The EGFR mutation status in tissue was tested by ADx-ARMS, matched plasma was detected by ddPCR and SuperARMS, respectively. RESULTS: The EGFR mutation rates were identified as 64.6% (tissue, ARMS), 55.7% (plasma, ddPCR), and 49.4% (plasma, Super ARMS), respectively. The sensitivity of ddPCR was similar with SuperARMS in plasma EGFR detection (80.4% vs 76.5%), as well as the specificity (89.3% vs 100%). And the McNemar's test showed there was no significant difference (P =.125). The concordance rate between SuperARMS and ddPCR was 91.1%. A significant interaction was observed between cfDNA EGFR mutation status and EGFR-TKIs treatment tested by both methods. CONCLUSION: Super-ARMS and ddPCR share the similar accuracy for EGFR mutation detection in plasma biopsy; both methods predicted well the efficacy of EGFR-TKIs by detecting plasma EGFR status.
引用
收藏
页码:542 / 545
页数:4
相关论文
共 20 条
[1]   Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J].
Bai, Hua ;
Mao, Li ;
Wang, Hang Shu ;
Zhao, Jun ;
Yang, Lu ;
An, Tong Tong ;
Wang, Xin ;
Duan, Chun Jian ;
Wu, Na Mei ;
Guo, Zhi Qing ;
Liu, Yi Xu ;
Liu, Hong Ning ;
Wang, Ye Yu ;
Wang, Jie .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2653-2659
[2]   The potential of liquid biopsies [J].
Buder, Anna ;
Tomuta, Christian ;
Filipits, Martin .
CURRENT OPINION IN ONCOLOGY, 2016, 28 (02) :130-134
[3]   Liquid Biopsies: Genotyping Circulating Tumor DNA [J].
Diaz, Luis A. ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (06) :579-+
[4]  
Duan HL, 2015, INT J CLIN EXP PATHO, V8, P13136
[5]   Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA [J].
Forshew, Tim ;
Murtaza, Muhammed ;
Parkinson, Christine ;
Gale, Davina ;
Tsui, Dana W. Y. ;
Kaper, Fiona ;
Dawson, Sarah-Jane ;
Piskorz, Anna M. ;
Jimenez-Linan, Mercedes ;
Bentley, David ;
Hadfield, James ;
May, Andrew P. ;
Caldas, Carlos ;
Brenton, James D. ;
Rosenfeld, Nitzan .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (136)
[6]   Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer [J].
Goto, Koichi ;
Ichinose, Yukito ;
Ohe, Yuichiro ;
Yamamoto, Nobuyuki ;
Negoro, Shunichi ;
Nishio, Kazuto ;
Itoh, Yohji ;
Jiang, Haiyi ;
Duffield, Emma ;
McCormack, Rose ;
Saijo, Nagahiro ;
Mok, Tony ;
Fukuoka, Masahiro .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (01) :115-121
[7]   Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma [J].
Li, Yuping ;
Xu, Hanyan ;
Su, Shanshan ;
Ye, Junru ;
Chen, Junjie ;
Jin, Xuru ;
Lin, Quan ;
Zhang, Dongqing ;
Ye, Caier ;
Chen, Chengshui .
PLOS ONE, 2017, 12 (08)
[8]   The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies [J].
Liu, Xiaoqing ;
Lu, Yachao ;
Zhu, Guanshan ;
Lei, Yao ;
Zheng, Li ;
Qin, Haifeng ;
Tang, Chuanhao ;
Ellison, Gillian ;
McCormack, Rose ;
Ji, Qunsheng .
JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (12) :1065-1069
[9]   Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy [J].
Mok, Tony ;
Wu, Yi-Long ;
Lee, Jin Soo ;
Yu, Chong-Jen ;
Sriuranpong, Virote ;
Sandoval-Tan, Jennifer ;
Ladrera, Guia ;
Thongprasert, Sumitra ;
Srimuninnimit, Vichien ;
Liao, Meilin ;
Zhu, Yunzhong ;
Zhou, Caicun ;
Fuerte, Fatima ;
Margono, Benjamin ;
Wen, Wei ;
Tsai, Julie ;
Truman, Matt ;
Klughammer, Barbara ;
Shames, David S. ;
Wu, Lin .
CLINICAL CANCER RESEARCH, 2015, 21 (14) :3196-3203
[10]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957